Aanandjit Sunderaj
Managing Director, Brookfield Corporation, Bermuda OperationsBrookfield
Fortune Global 500View Profile →Director, General Manager and Deputy Party Secretary · Sinopharm
Zhao Bingxiang is a director, general manager and deputy party secretary of Sinopharm. He previously worked in pharmaceutical sales, research and development, and executive management at China Resources pharmaceutical businesses.
Last reviewed: Nov 6, 2026
Director, General Manager and Deputy Party Secretary
Sinopharm
Last Reviewed: November 6, 2026
Zhao Bingxiang is a director, general manager and deputy party secretary of Sinopharm. He previously worked in pharmaceutical sales, research and development, and executive management at China Resources pharmaceutical businesses.
Zhao’s early pharmaceutical work included regional sales management and leadership of the market office at Sanjiu Pharmaceutical Trading. He subsequently became deputy general manager of Sanjiu Tongda Pharmaceutical. His career also included work as a senior researcher in China Resources Sanjiu’s research-and-development center and general manager of its Ya’an pharmaceutical business.
He later served as a vice president of China Resources Pharmaceutical Group, alongside chairman and general-manager responsibilities at China Resources Zizhu Pharmaceutical. In January 2022, China Resources Sanjiu appointed him president. His appointment biography recorded a national second-class science-and-technology progress award, a Sichuan special patent award and a provincial first-class science-and-technology award.
His professional service at that time included a vice presidency of the China Reproductive Health Industry Association and work as a professor and doctoral supervisor at Shenyang Pharmaceutical University. He also held board appointments across several China Resources pharmaceutical companies.
On March 13, 2024, Sinopharm announced his appointment as a parent director and deputy party secretary and nominated him for general manager. By the group’s November 2024 strategy workshop, he was serving as general manager and discussed market research, operating capabilities and the development of its next strategic plan.
He also chaired the separately listed Sinopharm Group. That subsidiary chairmanship passed to Jin Bin following the December 19, 2025 shareholder approval; Zhao’s current role is general manager of the parent group.
Zhao earned a bachelor’s degree from Shenyang Pharmaceutical University, a master’s degree from Peking University and a doctorate from Zhejiang University.